CA2915474A1 - Use of nk-1 receptor antagonist serlopitant in pruritus - Google Patents

Use of nk-1 receptor antagonist serlopitant in pruritus Download PDF

Info

Publication number
CA2915474A1
CA2915474A1 CA2915474A CA2915474A CA2915474A1 CA 2915474 A1 CA2915474 A1 CA 2915474A1 CA 2915474 A CA2915474 A CA 2915474A CA 2915474 A CA2915474 A CA 2915474A CA 2915474 A1 CA2915474 A1 CA 2915474A1
Authority
CA
Canada
Prior art keywords
serlopitant
cream
administered
day
ointment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2915474A
Other languages
English (en)
French (fr)
Inventor
Xiaoming Zhang
Edward F. Schnipper
Andrew J. Perlman
James W. Larrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vyne Therapeutics Inc
Original Assignee
Tigercat Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by Tigercat Pharma Inc filed Critical Tigercat Pharma Inc
Publication of CA2915474A1 publication Critical patent/CA2915474A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2915474A 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus Abandoned CA2915474A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
US61/838,784 2013-06-24
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Publications (1)

Publication Number Publication Date
CA2915474A1 true CA2915474A1 (en) 2014-12-31

Family

ID=51230173

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2915474A Abandoned CA2915474A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Country Status (13)

Country Link
EP (1) EP3013336A1 (enrdf_load_stackoverflow)
JP (2) JP2016523260A (enrdf_load_stackoverflow)
KR (1) KR20160023692A (enrdf_load_stackoverflow)
CN (1) CN105473138A (enrdf_load_stackoverflow)
AU (2) AU2014302694B2 (enrdf_load_stackoverflow)
BR (1) BR112015031724A2 (enrdf_load_stackoverflow)
CA (1) CA2915474A1 (enrdf_load_stackoverflow)
HK (1) HK1223820A1 (enrdf_load_stackoverflow)
IL (1) IL243189A0 (enrdf_load_stackoverflow)
MX (2) MX366728B (enrdf_load_stackoverflow)
PH (2) PH12015502777A1 (enrdf_load_stackoverflow)
RU (1) RU2666219C2 (enrdf_load_stackoverflow)
WO (1) WO2014209962A1 (enrdf_load_stackoverflow)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2016044784A1 (en) 2014-09-19 2016-03-24 Heron Therapeutics, Inc. Emulson formulations of aprepitant
WO2016141341A1 (en) 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
CA3013288A1 (en) * 2016-02-01 2017-08-10 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
JP2019519592A (ja) * 2016-06-29 2019-07-11 メンロ セラピューティクス インコーポレイテッド 様々な掻痒状態を処置するためのニューロキニン−１アンタゴニストの使用
KR20200054232A (ko) * 2017-09-13 2020-05-19 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
US11426408B2 (en) * 2017-11-01 2022-08-30 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
JP7324210B2 (ja) * 2018-01-31 2023-08-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド トファシチニブを含む局所製剤
CN115015440B (zh) * 2022-07-08 2024-10-15 江苏杜瑞制药有限公司 一种生物样品中纳呋拉啡的检测方法
CN117503699A (zh) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 阿瑞匹坦口服液制剂及制剂制造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
AR047439A1 (es) 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
CN100582093C (zh) * 2004-01-27 2010-01-20 默克公司 氢异二氢吲哚速激肽受体拮抗剂
DE602006020450D1 (de) 2005-07-11 2011-04-14 Merck Sharp & Dohme Ykinin-rezeptorantagonisten
US7893091B2 (en) 2005-10-04 2011-02-22 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
AU2007293393A1 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
EP2089019A4 (en) 2006-11-02 2011-05-04 Merck Sharp & Dohme POLYMORPHIC OF A HYDROISOINDOLINE TACHYKININE RECEPTOR ANTAGONIST
EP2141992A1 (en) 2007-03-29 2010-01-13 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (ru) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Гель, обладающий противовоспалительным и противоаллергическим действием

Also Published As

Publication number Publication date
JP2019142960A (ja) 2019-08-29
PH12020500255A1 (en) 2021-02-22
MX366728B (es) 2019-07-22
IL243189A0 (en) 2016-02-29
MX2015017763A (es) 2016-06-21
MX2019008643A (es) 2019-09-10
WO2014209962A1 (en) 2014-12-31
AU2014302694A1 (en) 2016-01-07
CN105473138A (zh) 2016-04-06
JP2016523260A (ja) 2016-08-08
PH12015502777A1 (en) 2016-03-21
EP3013336A1 (en) 2016-05-04
BR112015031724A2 (pt) 2017-07-25
AU2014302694B2 (en) 2019-10-17
HK1223820A1 (zh) 2017-08-11
RU2666219C2 (ru) 2018-09-06
AU2020200259A1 (en) 2020-02-06
RU2015154037A (ru) 2017-07-28
KR20160023692A (ko) 2016-03-03

Similar Documents

Publication Publication Date Title
US10702499B2 (en) Use of NK-1 receptor antagonists in pruritus
AU2014302694B2 (en) Use of NK-1 receptor antagonist serlopitant in pruritus
US11026920B2 (en) Use of NK-1 receptor antagonist serlopitant in pruritus
US20190216779A1 (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
EP3829572A1 (en) Use of neurokinin-1 antagonists to treat chronic pruritus
US20200121695A1 (en) Compositions and methods for treating itch, skin inflammation, and pruritus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190621

FZDE Discontinued

Effective date: 20220107